Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

Nature Biotechnology

Volumn 17, Issue 2, 1999, Pages 176-180

  Umaña, Pablo ^a   Jean Mairet, Joël ^a   Moudry, Radmila ^b   Amstutz, Hanspeter ^b   Bailey, James E ^a  

^a ETH ZURICH   (Switzerland)

^b Central Laboratory in Bern   (Switzerland)

Author keywords

Antitumor antibody; Effector function; Glycosylation; Tetracycline

Indexed keywords

CANCER ANTIBODY; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G1; N ACETYLGLUCOSAMINYLTRANSFERASE; TETRACYCLINE;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CARBOHYDRATE SEQUENCE; CHO CELLS; CRICETINAE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; N-ACETYLGLUCOSAMINYLTRANSFERASES; NEUROBLASTOMA; TETRACYCLINE;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0033044588     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/6179     Document Type: Article

References (26)

1. Deo, Y.M., Graziano, R.F., Repp, R., and van de Winkel, J.G.J. 1997. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol. Today 18:127-135.
2. Dillman, R.O. 1997. Magic bullets at last! Finally-approval of a monoclonal antibody for the treatment of cancer! Cancer Biother. Radiopharm. 12:223-225.
3. Frost, J.D., Hank, J.A., Reaman, G.H., Frierdich, S., Seeger, R.C., Gan, J. et al. 1997. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.2G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer 80:317-333.
4. Surfus, J.E., Hank, J.A., Oosterwijk, E., Welt, S., Lindstrom, M.J., and Albertini, M.R. 1996. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. 19:184-191.
5. Wright, A. and Morrison, S.L. 1997. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 15:26-31.
6. Wormald, M.R., Rudd, P.M., Harvey, D.J., Chang, S., Scragg, I.G., and Dwek, R.A. 1997. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the oligosaccharides. Biochemistry 36:1370-1380.
7. Lund, J., Takahashi, N., Pound, J.D., Goodall, M., Bentley, T., and Jefferis, R. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157:4963-4969.
8. Bergweff, A.A., Stroop, C.J., Murray, B., Holtorf, A.P., Pluschke, G., Van Oostrum, J., et al. 1995. Variation in N-linked carbohydrate chains in different batches of two chimeric monoclonal IgG1 antibodies produced by different murine SP2/0 transfectoma cell subclones. Glycoconj. J. 12:318-330.
9. Lifely, R.M., Hale, C., Boyce, S., Keen, M.J., and Phillips, J. 1995. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5:813-822.
10. Amstutz, H., Rytz. C., Novak-Hofer, I., Spycher, M., Schubiger, P.A., Blaser, K., and Morgenthaler, J.J. 1993. Production and characterization of a mouse/human chimeric antibody directed against human neuroblastoma. Int. J. Cancer 53:147-152.
11. Dürr, U., Haldemann, A.R., Leibundgut, K., Novak-Hofer, I., Amstutz, H., Wagner, H.P., et al. 1993. First clinical results with the chimeric antibody chCE7 in neuroblastoma. Targeting features and biodistribution data. Eur. J. Nucl. Med. 20:858.
12. Schachter, H. 1986. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Biochem. Cell Biol. 64:163-181.
13. Stanley, P. and Campbell, C.A. 1984. A dominant mutation to ricin resistance in Chinese hamster ovary cells induces UDP-GlcNac: glycopeptide β-4-N-Acetylglucosaminyl-transferase III activity. J. Biol. Chem. 261:13370-13378.
14. Nishikawa, A., Ihara, Y., Htakeyama, M., Kangawa, K., and Taniguchi, N. 1992. Purification, cDNA cloning, and expression of UDP-N-acetylglucosamine:β-D-mannoside β-1,4N-acetylglucosaminyltransferase III from rat kidney. J. Biol. Chem. 267:18199-18204.
15. Gossen, M. and Bujard, H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89:5547-5551.
16. Field, M., Papac, C., and Jones, A. 1996. The use of high-performance anionexchange chromatography and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to monitor and identify oligosaccharide degradation. Anal. Biochem. 239:92-98.
17. Harvey, D.J. 1993. Quantitative aspects of the matrix-assisted laser desorption mass spectrometry of complex oligosaccharides. Rapid Commun. Mass Spectrom. 7:614-619.
18. Knster, B., Wheeler, S.F., Hunter, A.P., Dwek, R.A., and Harvey, D.J. 1997. Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal. Biochem. 250:82-101.
19. Naven, T.J.P. and Harvey, D.J. 1996. Effect of structure on the signal strength of oligosaccharides in matrix-assisted laser desorption/ionization mass spectrometry on time-of-flight and magnetic sector instruments. Rapid Commun. Mass Spectrom. 10:1361-1366.
20. Yu lp, C.C., Miller, W.J., Silberklang, M., Mark, G.E., Ellis. R.W., Huang, L. et al. 1994. Structural characterization of the N-glycans of a humanized anti-CD18 murine immunoglobulin G. Arch. Biochem. Biophys. 308:387-399.
21. Bibila, T.A. and Robinson, D.K. 1995. In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol. Prog. 11:1-13.
22. Trill, J.J., Shatzman, A.R., and Ganguly, S. 1995. Production of monoclonal antibodies in COS and CHO cells. Curr. Opin. Biotechnol. 6:553-560.
23. Nilsson, T, Pypaert, M., Hoe, M.H., Slusarewicz, P., Berger, E.G., and Warren, G. 1993. Overlapping distribution of two glycosyltransferases in the Golgi apparatus of HeLa cells. J. Cell Biol. 120:5-13.
24. Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R. et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445.
25. Clackson, T, Güssow, D., and Jones, P.T. 1991. General applications of PCR to gene cloning and manipulation, pp. 187-214, in PCR: a practical approach. McPherson, M.J., Quirke, P., Taylor G.R. (eds.). Oxford University Press, Oxford, UK.
26. Kolber, M.A., Quinones, R.R., Gress, R.E., and Henkart, P.A. 1988. Measurement of cytotoxicity by target cell release and retention of the fluorescent dye bis-car-boxyethyl-carboxyfluorescein (BCECF). J. Immunol. Methods. 108:255-264.